Tower Research Capital (TRC)’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.38M | Buy |
22,531
+14,349
| +175% | +$1.56M | 0.08% | 217 |
|
|
2026
Q1 | $756K | Buy |
8,182
+5,439
| +198% | +$546K | 0.02% | 663 |
|
|
2025
Q4 | $280K | Buy |
2,743
+138
| +5% | +$12.3K | 0.01% | 1192 |
|
|
2025
Q3 | $163K | Sell |
2,605
-12,482
| -83% | -$679K | ﹤0.01% | 1634 |
|
|
2025
Q2 | $785K | Buy |
15,087
+11,163
| +284% | +$499K | 0.02% | 668 |
|
|
2025
Q1 | $167K | Sell |
3,924
-7,576
| -66% | -$327K | 0.01% | 1474 |
|
|
2024
Q4 | $351K | Buy |
11,500
+8,147
| +243% | +$229K | 0.01% | 1292 |
|
|
2024
Q3 | $76.9K | Sell |
3,353
-15,720
| -82% | -$445K | ﹤0.01% | 2448 |
|
|
2024
Q2 | $551K | Buy |
19,073
+18,414
| +2,794% | +$429K | 0.01% | 1257 |
|
|
2024
Q1 | $13.6K | Sell |
659
-25,297
| -97% | -$542K | ﹤0.01% | 3380 |
|
|
2023
Q4 | $702K | Buy |
25,956
+24,470
| +1,647% | +$642K | 0.01% | 1106 |
|
|
2023
Q3 | $44K | Sell |
1,486
-1,995
| -57% | -$70.2K | ﹤0.01% | 2653 |
|
|
2023
Q2 | $125K | Sell |
3,481
-28,561
| -89% | -$820K | ﹤0.01% | 1901 |
|
|
2023
Q1 | $751K | Buy |
32,042
+31,180
| +3,617% | +$891K | 0.02% | 595 |
|
|
2022
Q4 | $23K | Sell |
862
-1,236
| -59% | -$56.6K | ﹤0.01% | 2993 |
|
|
2022
Q3 | $113K | Sell |
2,098
-765
| -27% | -$39.3K | ﹤0.01% | 2460 |
|
|
2022
Q2 | $116K | Buy |
2,863
+1,414
| +98% | +$70.1K | ﹤0.01% | 2174 |
|
|
2022
Q1 | $96K | Sell |
1,449
-3,781
| -72% | -$259K | ﹤0.01% | 2227 |
|
|
2021
Q4 | $523K | Buy |
5,230
+3,035
| +138% | +$314K | 0.01% | 1082 |
|
|
2021
Q3 | $275K | Sell |
2,195
-2,610
| -54% | -$310K | 0.01% | 1503 |
|
|
2021
Q2 | $597K | Buy |
4,805
+3,981
| +483% | +$535K | 0.02% | 1035 |
|
|
2021
Q1 | $126K | Sell |
824
-3,237
| -80% | -$489K | ﹤0.01% | 2400 |
|
|
2020
Q4 | $523K | Buy |
4,061
+3,320
| +448% | +$382K | 0.02% | 956 |
|
|
2020
Q3 | $83K | Buy |
741
+526
| +245% | +$48.1K | ﹤0.01% | 3287 |
|
|
2020
Q2 | $17K | Buy |
+215
| New | +$17.3K | ﹤0.01% | 3758 |
|
|
2020
Q1 | – | Sell |
-92
| Closed | -$7K | – | 3348 |
|
|
2019
Q4 | $7K | Buy |
92
+57
| +163% | +$4.11K | ﹤0.01% | 2515 |
|
|
2019
Q3 | $2K | Buy |
+35
| New | +$3.08K | ﹤0.01% | 3683 |
|
|
2019
Q2 | – | Sell |
-2,136
| Closed | -$164K | – | 3897 |
|
|
2019
Q1 | $164K | Buy |
2,136
+2,133
| +71,100% | +$118K | 0.01% | 1213 |
|
|
2018
Q4 | $0 | Buy |
+3
| New | +$111 | ﹤0.01% | 4008 |
|
Other funds holding GH
DTC
Tower Research Capital (TRC)'s GH Position: Q2 2026 in Review
Tower Research Capital (TRC) increased its Guardant Health (GH) stake by 175% in Q2 2026, buying an estimated $1.56M and bringing the position to 22,531 shares worth $3.38M. The position accounts for 0.08% of the portfolio, ranked #217.
Tower Research Capital (TRC) first reported a position in GH in Q4 2018 and has held it in 29 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Tower Research Capital (TRC) held 22,531 shares of Guardant Health worth $3.38M as of Q2 2026.
- Tower Research Capital (TRC) bought 14,349 Guardant Health shares in Q2 2026, an estimated $1.56M.
- Guardant Health made up 0.08% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #217 holding.
- Tower Research Capital (TRC) first reported a position in Guardant Health in Q4 2018 and has held it in 29 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.